Affimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Heidelberg, Germany, February 8, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners 6^th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:00 a.m. (ET) in New York.

A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

IR Contact:

Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]

Media Contact:

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]